Xcout Intel
F2G
F2G is a biotechnology research company headquartered in the UK with subsidiaries in the US and Austria. The company specializes in developing novel therapeutics and antifungal treatments for rare fungal infections.
Subscribe to see F2G’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
F2G at a glance
F2G is a biopharmaceutical company headquartered in United Kingdom. It has raised at least $220.8M across the 3 funding rounds on record. Its most recent funding round raised $100M in September 2024. Xcout tracks 20 named people at F2G, including Francesco Maria Lavino (Chief Executive Officer).
F2G leadership
- Francesco Maria LavinoChief Executive Officer
- Mike Birch, PhDChief Operating Officer
- Ralf SchmidChief Financial Officer
- Janelle R. Anderson, PhDChief Business Officer
- John H. Rex, MDChief Medical Officer
- Mark BaglinChief Commercial Officer
14 more named people on record for F2G, with roles, board committees and tenure — see the full roster →
F2G funding rounds
At least $220.8M raised across the 3 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | $100M | 10 named | |
| — | $60.8M | 11 named | |
| — | $60M | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
F2G competitors
A few of F2G's closest competitors — see the full list of competitors and alternatives →
Amplyx Pharmaceuticals, Inc. was a San Diego-based clinical-stage biotechnology company developing treatments for serious and potentially life-threatening fungal infections. Its lead investigational drug, fosmanogepix, was acquired by Pfizer when Pfizer acquired Amplyx in 2021 and is being developed for patients with invasive fungal diseases.
Cidara Therapeutics, Inc. is a biotechnology company focused on developing late-phase antiviral and immunotherapy agents, with operations based in San Diego, California and Rahway, New Jersey.
Pulmocide is a UK drug-discovery and development company focused on inhaled treatments for serious fungal lung infections. Its lead candidate, opelconazole (PC945), is an inhaled antifungal being developed for pulmonary aspergillosis and related respiratory fungal diseases, serving patients with difficult-to-treat pulmonary infections.
CAGE Bio is a clinical-stage biotechnology company that develops localized therapies for dermatology, inflammation, and immunology. The company utilizes a proprietary deep eutectic ionic liquid platform to enable the skin penetration of small and large molecules, providing topical treatments designed to avoid the side effects of systemic drug exposure.
Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate.
Achaogen Inc was a biopharmaceutical company headquartered in South San Francisco, California. The company focused on discovering, developing, and commercializing novel antibacterial treatments.
Get F2G's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on F2G in Xcout Intel
- 20 named people with titles, LinkedIn and board committees
- 3 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access